FDA issued a warning letter to a Chinese supplier, Harbin Jixianglong Biotech, after inspectors found alleged compliance failures tied to the agency’s GLP-1 import restrictions. FDA said the company purchased semaglutide API from a facility not on the FDA “green list,” then allegedly relabeled APIs to appear manufactured at an approved site. The warning letter follows FDA’s September 2025 move to restrict GLP-1 active ingredients from unverified foreign sources, including shipment detentions from non-authorized facilities. FDA cited risks that substandard semaglutide APIs could reach the US market if safeguards are circumvented. Companies across the GLP-1 supply chain are likely to face renewed scrutiny on supplier qualification, batch records, and documentation for repackaging and relabeling.